Gilead Sciences, Inc.

Megan E Neubig

Joshua A Kaplan

Petr Jansa

Christopher T Clark

Kirk L Stevens

Jennifer R Lo

Kin Shing Yang

Daniel H Byun

Anna Zagorska

Brian P Bestvater

Zachary A Kasun

Nathaniel H Stanley

James L Bachman

Compounds of formula: wherein the variable substituents are defined herein.

KHK inhibitors

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (TLD), or chronic kidney disease (CKD).

LPA receptor antagonists and uses thereof

Growing community of inventors

San Diego, CA, United States of America

Megan E Neubig